Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States.
FAIL · Does not pass the screen
37.18 USD
At the last full screen 2026-08-27
Screened 2026-08-27 · the tape above runs as of 10:31 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markup label.
Amylyx Pharmaceuticals, Inc. holds its Markup at $37.18. Elevated stress, defensive posture warranted, held for 13 days.
As held on the ledger · 2026-08-27
Phase
Markup
Quantitative state
Elevated stress, defensive posture warranted, held for 13 days
Price at the screen
$37.18
Valuation
N/A trailing · -32.20 forward price to earnings
Values screen
FAIL· score 70.0
Beta
-0.21
The Workings
Five Screens, Shown in Full
Does not pass. Accounts receivable
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
1.79%
Below 33%
Interest-bearing debt is just 1.8% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
27.15%
Below 33%
Cash held in interest-bearing accounts and securities is 27.2% of assets, under the one-third limit.
Pass
Receivables
68.16%
Below 49%
Money owed to the company is 68.2% of assets, above the 49% limit.
Fail
Revenue purity
Excluded
Below 5%
of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-08-27 screen. The gold marker is the market price at the same screen. A 13.0% margin of safety to the base estimate.
Third-party analyst targets: 11 covering, consensus Strong Buy. The average target sits +13% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-08-27 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Early Biotech With No Numbers To Judge
Picture a lab racing to treat cruel brain diseases with one experimental drug and nothing else on the shelf. Amylyx shows zero profit margin, a negative 63 percent return on equity and a forward multiple that sits at minus 14 times because earnings remain absent. The opportunity rating sits at none and the ethical screen flags insufficient data, so we pass without hesitation.
The shares trade at 17.75 dollars against an internal fair value of 21.50, yet that gap means little when the business is still clinical stage and carries an unknown moat. Ten analysts offer a median target near 22 dollars, but the absence of any usable financial ratios leaves the usual checks impossible to run.
Risk sits in the complete lack of earnings visibility and the ethical data hole that blocks any further review. Without those basics the story stays untestable, regardless of disease area or future hopes. Analysis, not advice.
The risks · The things to watch: as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
AMLX trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-21Markup · changed$23.35+31.5%Entry 6
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 31.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 4% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 132%. Our forward projection puts the odds of a 10% gain over the next month near 50%. The street (10 analysts) rates it none, with a mean price target of $23.
2026-07-21Markdown$17.75+21.7%Entry 5
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 21.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 4% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 132%. Our forward projection puts the odds of a 10% gain over the next month near 50%. The street (10 analysts) rates it none, with a mean price target of $23.
2026-07-18Markdown$14.59+0.0%Entry 4
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 4% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 132%. Our forward projection puts the odds of a 10% gain over the next month near 50%. The street (10 analysts) rates it none, with a mean price target of $23.
2026-07-17Markdown$14.59+0.0%Entry 3
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 4% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 132%. Our forward projection puts the odds of a 10% gain over the next month near 50%. The street (10 analysts) rates it none, with a mean price target of $23.
2026-07-03Markdown$14.59+0.0%Entry 2
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markdown$14.59Entry 1
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
